Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30750882 | 1.00 | TSHR (0.56) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL25908466 | 0.84 | ALDH1A1 (0.50) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL29938143 | 0.83 | ALDH1A1 (0.48) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL2994229 | 0.83 | ALDH1A1 (0.48) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL5351652 | 0.83 | ALDH1A1 (0.48) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL9198448 | 0.83 | ALDH1A1 (0.48) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL171825 | 0.82 | TSHR (0.61) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL29766284 | 0.82 | TSHR (0.61) | TSHRGAAGLAPOLBALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL31491052 | 0.82 | GAA (0.40) | TSHRGAAGLAPOLBALDH1A1 | |
| SCHEMBL10021502 | 0.79 | GAA (0.77) | TSHRGAAGLAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2026042018-A1 | 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES | PFIZER INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4695226-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1207874-A4 | METHODS OF TREATING PROLIFERATIVE DISORDERS | BIOMEDICINES INC (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6649635-B2 | For therapy of cancer | SUGEN, INC. | 2003-11-18 | — | — | US | disclosed |
| US-6566395-B1 | Therapy of proliferative disorders, such as cancers, blood vessel disorders and fibrotic disorders by administering N-(3-methyl-4- trifluoromethylphenyl) 2-cyano-2-(cycloalkylcarbonyl)acetamide compounds | BIOMEDICINES, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | MCMAHON GERALD (US) | 2002-05-30 | — | — | US | disclosed |
| EP-1207874-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS | Biomedicines, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6316479-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2000071113-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS | BIOMEDICINES, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| US-4731450-A | Process for perfluoroalkylation of aromatic derivatives | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-03-15 | — | — | US | disclosed |
| US-4261926-A | REACTION WITH KETONE IN PRESENCE OF PLATINUM HYDROGENATION CATALYST AND A PROMOTER ACID | AMERICAN CYANAMID COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | TSHR 3993/4885GAA 2385/4885GLA 3419/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | TSHR 3993/4885GAA 2385/4885GLA 3419/4885 |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | TSHR 24/4885GAA 1535/4885GLA 1890/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | TSHR 3993/4885GAA 2385/4885GLA 3419/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | TSHR 263/4885GAA 3456/4885GLA 2147/4885 |
| US-20020065283-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | TSHR 2483/4885GAA 1134/4885GLA 3974/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | TSHR 2091/4885GAA 4548/4885GLA 3799/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | TSHR 37/4885GAA 633/4885GLA 2534/4885 |
| US-20040102489-A1 | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders | ABL1, ERBB2, PRKDC | TSHR 2483/4885GAA 1134/4885GLA 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.